On January 11, 2018, Celltrion and Teva filed two lawsuits against Genentech in the District Court for the Northern District of California.  Case No. 3:18-cv-00274 relates to Celltrion’s Herzuma®, its trastuzumab biosimilar.  According to the complaint, Celltrion and Teva seek a declaratory judgment of non-infringement, invalidity, and/or unenforceability of 38 patents.  Case No. 3:18-cv-00276 relates to Celltrion’s Truxima®, its rituximab biosimilar.  According to the complaint, Celltrion and Teva seek a declaratory judgment of non-infringement and invalidity of 37 patents.

On January 12, 2018, Genentech filed its own lawsuits against Celltrion and Teva.   Case No. 1-18-cv-00095, filed in the District Court for the District of Delaware, relates to Celltrion’s Herzuma® product.  According to the Delaware complaint, Genentech seeks a judgment of infringement of 40 patents.  Case No. 1:18-cv-000-574, filed in the District Court for the District of New Jersey, relates to Celltrion’s Truxima® product.  According to the New Jersey complaint, Genentech seeks a judgment of infringement of 40 patents.